Oncotelic Therapeutics, Inc.: cash and cash equivalents
Oncotelic Therapeutics cash and cash equivalents: $170.4 thousand at 2023-12-31, down 29.4% on the year. 15 values since 2008, each linked to its SEC filing.
All Oncotelic Therapeutics, Inc. financial histories
At a glance
Oncotelic Therapeutics reported cash and cash equivalents of $170.4 thousand at 2023-12-31, down 29.4% from $241.5 thousand a year earlier. From 2008 to 2023 it fell at a compound 26.8% a year, from $18.3 million to $170.4 thousand. Across the last five reported years it ranged from $82.0 thousand (2019-12-31) to $568.8 thousand (2021-12-31). That was 0.6% of total assets ($30.0 million) at the same date.
Computed from the values in the table below, in USD; each links to the filing it came from.
What this measure means
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
Exact concept: us-gaap:CashAndCashEquivalentsAtCarryingValue. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2008-12-31 to 2023-12-31. The SEC response was captured on 2026-09-20.
This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| - | 2023-12-31 | 170,405 | USD | 2024-04-12 | 10-K · 0001493152-24-014475 SEC |
| - | 2022-12-31 | 241,452 | USD | 2024-04-12 | 10-K · 0001493152-24-014475 SEC |
| - | 2021-12-31 | 568,769 | USD | 2023-04-20 | 10-K/A · 0001493152-23-012978 SEC |
| - | 2020-12-31 | 474,019 | USD | 2022-04-15 | 10-K · 0001493152-22-010094 SEC |
| - | 2019-12-31 | 81,964 | USD | 2021-04-15 | 10-K · 0001493152-21-008920 SEC |
| - | 2018-12-31 | 2,498 | USD | 2020-05-14 | 10-K · 0001493152-20-008845 SEC |
| - | 2017-12-31 | 1,115,000 | USD | 2019-04-10 | 10-K · 0001193125-19-102832 SEC |
| - | 2016-12-31 | 3,535,000 | USD | 2019-04-10 | 10-K · 0001193125-19-102832 SEC |
| - | 2015-12-31 | 27,285,000 | USD | 2018-04-17 | 10-K · 0001193125-18-119206 SEC |
| - | 2014-12-31 | 30,031,000 | USD | 2017-03-30 | 10-K · 0001193125-17-103621 SEC |
| - | 2012-12-31 | 4,946,000 | USD | 2013-03-15 | 10-K · 0001193125-13-110175 SEC |
| - | 2011-12-31 | 9,972,000 | USD | 2013-03-15 | 10-K · 0001193125-13-110175 SEC |
| - | 2010-12-31 | 4,602,000 | USD | 2013-03-15 | 10-K · 0001193125-13-110175 SEC |
| - | 2009-12-31 | 13,932,000 | USD | 2013-03-15 | 10-K · 0001193125-13-110175 SEC |
| - | 2008-12-31 | 18,275,000 | USD | 2012-03-28 | 10-K · 0001193125-12-137327 SEC |
Related Oncotelic Therapeutics, Inc. histories
Inspect the source
- Entity
- Oncotelic Therapeutics, Inc. / CIK 0000908259
- Captured
- SEC response SHA-256
6c0026f9e455c874f284117994b59a028bad3a82bccf268424724837d8c3b9db
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000908259.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))